Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-07
2005-06-07
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S186000, C514S521000, C514S638000, C514S742000, C424S184100, C424S279100
Reexamination Certificate
active
06903100
ABSTRACT:
The present invention is directed to the treatment of multiple sclerosis by periodically administering a high dose of methotrexate at a level sufficiently high to cross the blood brain barrier. The methotrexate administration is accompanied by leucovorin rescue of the periphery. The high dose methotrexate is preferably administered at 1 to 4 month intervals. The periodic high dose methotrexate treatment may be used in conjunction with interim treatments using a therapeutic agent that is effective in treating MS, but does not cross the BBB in cytotoxic amounts. It is contemplated that the method of the present invention may be employed to treat other non-infectious, non-neoplastic inflammatory conditions of the CNS.
REFERENCES:
patent: 5166149 (1992-11-01), Loev
patent: 5935577 (1999-08-01), Weiner et al.
Uria, D. F., Treatment of Multiple Sclerosis, Neurologia, 1999, 14/Suppl. 6, pp. 1-12, abstract.
Goodkin, et al., Low Dose (7.5 mg) Oral Methotrexate reduces the rate of progression in chronic progressive multiple sclerosis,Ann Neurol, 1995, 37:30-40.
Weiner, et al., Intermittent Cyclophosphamide Pulse Therapy in Progressive Multiple Sclerosis: Final Report of the Northeast Cooperative Multiple Sclerosis Treatment Group,Neurology, 1993, 43: 910-8.
Cronstein, The Mechanism of Actin of Methotrexate,Rheum Dis Clin North Am, 1997, 23: 739-55.
Glantz, et al., High-Dose Intravenous Methotrexate for Patients With Nonleukemic Sarcoma Leptomeningeal Cancer: Is Intrathecal Chemotherapy Necessary?,J Clin Oncol, 1998, 16: 1561-7.
Pignon, et al., Pharmacokinetics of High-Dose Methotrexate in Adult Osteogenic Sarcoma,Cancer Chemother Pharmacol, 1994, 33: 420-4.
Balis, Remission Induction of Meningeal Leukemia With High-Dose Intravenous Methotrexate,J Clin Oncol, 1985, 3: 485-9.
Doolittle, et al., Safety and Efficacy of a Multicenter Study Using Intraarterial Chemotherapy in Conjunction With Osmotic Opening of the Blood-Brain barrier for the Treatment of Patients With Malignant Brain Tumors,Cancer, 2000, 88: 637-47.
Neuwelt, et al., Primary CNS Lymphoma Treated With Osmotic Blood-Brain Barrier Disruption: Prolonged Survival and Preservation of Cognitive Function,J Clin Oncol, 1991, 9: 1580-90.
Wang, et al., Methotrexate Pulse Therapy on MSFC and Cellular Immunology Markers in Patients With Relapsing Progressive Multiple Sclerosis,Neurology, 2001, 56, Suppl. 3: A365.
Currier, et al., Low Dose Oral Methotrexate Treatment of Multiple Sclerosis: A Pilot Study [published erratum appears inJ Neurol Neurosurg PsychiatryApr. 1999; 57(4): 528].J Neurosurg Psychiatry, 1993, 56: 1217-8.
Goodkin, et al., Low-Dose Oral Methotrexate in Chronic Progressive Multiple Sclerosis: Analyses of Serial MRIs.,Neurology, 1996, 47: 1153-7.
Rensel, et al., Oral Methotrexate Dose Escalation Study in Progressive Multiple Sclerosis,Ann Neurol, 1997, 42: 423.
Tetef, et al., Pharmacokinetics and Toxicity of High-Dose Intravenous Methotrexate in the Treatment of Leptomeningeal Carcinomatosis,Cancer Chemother Pharmacol, 2000, 46: 19-26.
Conrad, et al., Treatment of Primary and Secondary Progressive Multilple Sclerosis with High Dose Methotrexate and Leucovorin Rescue,Neurology, 1998: 50: A-146.
Mid America Neuroscience Research Foundation, Study Suggests New Hope for Patents Suffering from Progressive Multiple Sclerosis,The Neurology Newsletter, 1998, pp. 1-4.
MidAmerica Neuroscience Research Foundation
Shughart Thomson & Kilroy P.C.
LandOfFree
USE OF REGULARLY SCHEDULED HIGH DOSE INTRAVENOUS... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with USE OF REGULARLY SCHEDULED HIGH DOSE INTRAVENOUS..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and USE OF REGULARLY SCHEDULED HIGH DOSE INTRAVENOUS... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467291